AR097657A1 - Vectores de virus adenoasociados de factor viii - Google Patents
Vectores de virus adenoasociados de factor viiiInfo
- Publication number
- AR097657A1 AR097657A1 ARP140103423A ARP140103423A AR097657A1 AR 097657 A1 AR097657 A1 AR 097657A1 AR P140103423 A ARP140103423 A AR P140103423A AR P140103423 A ARP140103423 A AR P140103423A AR 097657 A1 AR097657 A1 AR 097657A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- sequence
- construct
- established
- fviii
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La solicitud proporciona vectores de virus adenoasociados (AAV) de Factor VIII (FVIII), que incluyen vectores AAV de FVIII que producen un polipéptido de Factor VIII funcional y vectores AAV de FVIII con actividad de expresión alta. Reivindicación 2: El vector AAV de FVIII de la reivindicación 1, donde el ácido nucleico comprende una secuencia de nucleótidos seleccionada del grupo que consiste en: i) la secuencia Proto 1 establecida en SEQ ID Nº 1, ii) la secuencia Proto 1S establecida en SEQ ID Nº 2, iii) la secuencia Proto 25 establecida en SEQ ID Nº 3, iv) la secuencia Proto 3S establecida en SEQ ID Nº 4, v) la secuencia Proto 4 establecida en SEQ ID Nº 5, vi) la secuencia Proto 5 establecida en SEQ ID Nº 6, vii) la secuencia Proto 6 establecida en SEQ ID Nº 7, viii) la secuencia Proto 7 establecida en SEQ ID Nº 8, ix) la secuencia Construct 100ATG establecida en SEQ ID Nº 9, x) la secuencia Construct 100ATG bGH poly A establecida en SEQ ID Nº 10, xi) la secuencia Construct 100ATG short bGH poly A establecida en SEQ ID Nº 11, xii) la secuencia Construct 103ATG establecida en SEQ ID Nº 12, xiii) la secuencia Construct 103ATG short bGH poly A establecida en SEQ ID Nº 13, xiv) la secuencia Construct 105ATG bGH poly A establecida en SEQ ID Nº 14, xv) la secuencia Construct DC172ATG FVIII establecida en SEQ ID Nº 15, xvi) la secuencia Construct DC172 ATG FVIII hAAT establecida en SEQ ID Nº 16, xvii) la secuencia Construct DC172 2xHCR ATG FVIII establecida en SEQ ID Nº 17, xviii) la secuencia Construct DC172 2xHCR ATG FVIII hAAT establecida en SEQ ID Nº 18, xix) la secuencia Construct 2x SerpinAhAAT ATG FVIII establecida en SEQ ID Nº 19, xx) la secuencia Construct 2x SerpinAhAAT ATG FVIII 2x potenciador de micro-globulina establecida en SEQ ID Nº 20, xxi) la secuencia Construct 100ATG short poly A 2x potenciador de micro-globulina establecida en SEQ ID Nº 21, xxii) la secuencia Construct Factor VIII-BMN001 establecida en SEQ ID Nº 22, xxiii) la secuencia Construct Factor VIII-BMN002 establecida en SEQ ID Nº 23, xxiv) la secuencia Construct 99 establecida en SEQ ID Nº 24, xxv) la secuencia Construct 100 establecida en SEQ ID Nº 25, xxvi) la secuencia Construct 100 sentido inverso establecida en SEQ ID Nº 26, xxvii) la secuencia Construct 100AT establecida en SEQ ID Nº 27, xxviii) la secuencia Construct 100AT 2x MG establecida en SEQ ID Nº 28, xxix) la secuencia Construct 100AT 2x MG poly A establecida en SEQ ID Nº 29, xxx) la secuencia Construct 100AT 2x MG (inversa) bGH poly A establecida en SEQ ID Nº 30, xxxi) la secuencia Construct 100 bGH poly A establecida en SEQ ID Nº 31, xxxii) la secuencia Construct 100-400 establecida en SEQ ID Nº 32, xxxiii) la secuencia Construct 101 establecida en SEQ ID Nº 33, xxxiv) la secuencia Construct 102 establecida en SEQ ID Nº 34, xxxv) la secuencia Construct 103 establecida en SEQ ID Nº 35, xxxvi) la secuencia Construct 103 sentido inverso establecida en SEQ ID Nº 36, xxxvii) la secuencia Construct 103AT establecida en SEQ ID Nº 37, xxxviii) la secuencia Construct 103AT 2x MG establecida en SEQ ID Nº 38, xxxix) la secuencia Construct 103AT 2x MG poly A establecida en SEQ ID Nº 39, xl) la secuencia Construct 103 bGH poly A establecida en SEQ ID Nº 40, xli) la secuencia Construct 104 establecida en SEQ ID Nº 41, xlii) la secuencia Construct 105 establecida en SEQ ID Nº 42, xliii) la secuencia Construct 106 establecida en SEQ ID Nº 43, xliv) la secuencia Construct 106AT establecida en SEQ ID Nº 44 y xlv) la secuencia Construct 2x SerpinA hAAT establecida en SEQ ID Nº 45.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361877042P | 2013-09-12 | 2013-09-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR097657A1 true AR097657A1 (es) | 2016-04-06 |
Family
ID=51585244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140103423A AR097657A1 (es) | 2013-09-12 | 2014-09-12 | Vectores de virus adenoasociados de factor viii |
Country Status (33)
| Country | Link |
|---|---|
| US (5) | US9504762B2 (es) |
| EP (2) | EP3770169A1 (es) |
| JP (4) | JP6735672B2 (es) |
| KR (2) | KR102484396B1 (es) |
| CN (2) | CN112538501A (es) |
| AR (1) | AR097657A1 (es) |
| AU (1) | AU2014318890B2 (es) |
| CA (3) | CA3178384A1 (es) |
| CL (1) | CL2016000502A1 (es) |
| CY (1) | CY1124213T1 (es) |
| DK (1) | DK3044231T3 (es) |
| ES (1) | ES2813698T3 (es) |
| FI (1) | FIC20230007I1 (es) |
| FR (1) | FR23C1007I1 (es) |
| HK (1) | HK1226416A1 (es) |
| HR (1) | HRP20201324T1 (es) |
| HU (2) | HUE050484T2 (es) |
| IL (2) | IL244404B (es) |
| LT (2) | LT3044231T (es) |
| MX (2) | MX2016003262A (es) |
| NL (1) | NL301222I2 (es) |
| NO (1) | NO2023003I1 (es) |
| NZ (1) | NZ716549A (es) |
| PE (1) | PE20160769A1 (es) |
| PH (1) | PH12016500328A1 (es) |
| PL (1) | PL3044231T3 (es) |
| PT (1) | PT3044231T (es) |
| RS (1) | RS61039B1 (es) |
| RU (1) | RU2710307C2 (es) |
| SG (1) | SG11201601932UA (es) |
| SI (1) | SI3044231T1 (es) |
| TW (1) | TWI632239B (es) |
| WO (1) | WO2015038625A1 (es) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201210357D0 (en) | 2012-06-12 | 2012-07-25 | Ucl Business Plc | Factor VIII sequences |
| CN112538501A (zh) | 2013-09-12 | 2021-03-23 | 生物马林药物股份有限公司 | 腺相关病毒因子viii载体 |
| WO2016073693A2 (en) | 2014-11-05 | 2016-05-12 | Voyager Therapeutics, Inc. | Aadc polynucleotides for the treatment of parkinson's disease |
| GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
| JP6879486B2 (ja) | 2015-03-17 | 2021-06-02 | フリーイェ・ユニヴェルシテイト・ブリュッセルＶｒｉｊｅ Ｕｎｉｖｅｒｓｉｅｉｔ Ｂｒｕｓｓｅｌ | Ｆｖｉｉｉおよびｆｉｘ用の最適化された肝臓特異的発現系 |
| TWI707951B (zh) | 2015-04-08 | 2020-10-21 | 美商健臻公司 | 過大腺相關載體之製造 |
| US10058624B2 (en) * | 2015-04-16 | 2018-08-28 | Emory University | Recombinant promoters and vectors for protein expression in liver and use thereof |
| BR112018006074A2 (pt) * | 2015-09-24 | 2018-10-09 | Biomarin Pharm Inc | vetores de fator viii de vírus adeno-associado, partículas virais associadas e formulações terapêuticas compreendendo as mesmas |
| BR112018008519A2 (pt) | 2015-10-28 | 2018-11-06 | Sangamo Therapeutics Inc | construtos específicos de fígado, cassetes de expressão de fator viii e métodos de uso dos mesmos |
| PE20231949A1 (es) * | 2015-10-30 | 2023-12-05 | Spark Therapeutics Inc | VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA |
| CN108602876B (zh) * | 2015-11-13 | 2022-07-05 | 武田药品工业株式会社 | 用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体 |
| SG10202106307UA (en) * | 2015-11-13 | 2021-07-29 | Takeda Pharmaceuticals Co | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a |
| MX2018012537A (es) * | 2016-04-15 | 2019-02-25 | Univ Pennsylvania | Terapia de genes para tratar hemofilia a. |
| CA3023473A1 (en) | 2016-05-25 | 2017-11-30 | Lonza Houston Inc. | Methods for isolating adeno-associated virus using a polydiallyldialkylammonium salt |
| US11584780B2 (en) | 2016-07-26 | 2023-02-21 | Biomarin Pharmaceutical Inc. | Adeno-associated virus capsid proteins |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| KR20200066289A (ko) * | 2017-08-01 | 2020-06-09 | 스파크 테라퓨틱스, 인코포레이티드 | 인자 viii (fviii) 유전자 요법 방법 |
| KR20210008501A (ko) | 2018-05-09 | 2021-01-22 | 바이오마린 파머수티컬 인크. | 페닐케톤뇨증을 치료하는 방법 |
| TW202005978A (zh) | 2018-05-14 | 2020-02-01 | 美商拜奧馬林製藥公司 | 新穎肝靶向腺相關病毒載體 |
| EP3794112A1 (en) | 2018-05-14 | 2021-03-24 | BioMarin Pharmaceutical Inc. | Stable expression of aav vectors in juvenile subjects |
| EP3823985A1 (en) | 2018-07-16 | 2021-05-26 | Baxalta Incorporated | Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression |
| EP3799569A1 (en) * | 2018-07-27 | 2021-04-07 | Zentrum für Forschungsförderung in der Pädiatrie GmbH | Improved concepts for the treatment of genetic disorders with high-capacity plal-generated gold nanoparticles |
| US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
| EP3863662A1 (en) * | 2018-10-12 | 2021-08-18 | Genzyme Corporation | Generation of improved human pah for treatment of severe pku by liver-directed gene replacement therapy |
| TW202039546A (zh) | 2019-01-16 | 2020-11-01 | 美商巴克斯歐塔公司 | 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體 |
| AU2020221340A1 (en) | 2019-02-15 | 2021-09-16 | Bayer Healthcare Llc | Gene editing for hemophilia A with improved Factor VIII expression |
| SG11202109850SA (en) * | 2019-03-13 | 2021-10-28 | Generation Bio Co | Non-viral dna vectors and uses thereof for expressing fviii therapeutics |
| JP6831943B1 (ja) | 2019-10-24 | 2021-02-17 | 三ツ星ベルト株式会社 | 摩擦伝動ベルトおよびその製造方法 |
| JP2023501262A (ja) * | 2019-11-01 | 2023-01-18 | フリーライン セラピューティクス リミテッド | 転写調節エレメント |
| US20230023826A1 (en) | 2019-12-12 | 2023-01-26 | Takeda Pharmaceutical Company Limited | Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression |
| WO2021236908A2 (en) | 2020-05-20 | 2021-11-25 | Biomarin Pharmaceutical Inc. | Use of regulatory proteins for the production of adeno-associated virus |
| CA3196778A1 (en) | 2020-11-02 | 2022-05-05 | Biomarin Pharmaceutical, Inc. | Process for enriching adeno-associated virus |
| CN117858895A (zh) | 2021-06-14 | 2024-04-09 | 武田药品工业株式会社 | 使用表达增强的编码重组fviii变体的病毒载体的血友病a基因疗法 |
| EP4359547A1 (en) * | 2021-06-22 | 2024-05-01 | Pfizer Inc. | Production of adeno-associated virus vector in insect cells |
| CA3227296A1 (en) * | 2021-07-28 | 2023-02-02 | Tomas Cinek | Large scale adeno-associated virus production systems |
| CA3229323A1 (en) * | 2021-08-23 | 2023-03-02 | Ajay MAGHODIA | Optimized factor viii genes |
| WO2023036054A2 (en) * | 2021-09-08 | 2023-03-16 | Inspirar Limited | Composition and method for treating hemophilia |
| WO2023135273A2 (en) | 2022-01-14 | 2023-07-20 | Anjarium Biosciences Ag | Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof |
| TW202400796A (zh) * | 2022-03-11 | 2024-01-01 | 美商同源醫藥公司 | 雙向雙重啟動子表現載體及其用途 |
| WO2023205300A2 (en) * | 2022-04-20 | 2023-10-26 | Asklepios Biopharmaceutical, Inc. | Therapeutic adeno-associated virus using codon optimized nucleic acid encoding factor viii |
| WO2024064856A1 (en) | 2022-09-22 | 2024-03-28 | Biomarin Pharmaceutical Inc. | Treatment of cardiomyopathy with aav gene therapy vectors |
| WO2024064863A2 (en) | 2022-09-22 | 2024-03-28 | Biomarin Pharmaceutical Inc. | Treatment of arrhythmogenic cardiomyopathy with aav gene therapy vectors |
| CN115948408A (zh) * | 2022-09-23 | 2023-04-11 | 上海信致医药科技有限公司 | 改进的人凝血因子viii基因表达盒及其应用 |
| WO2024074143A1 (en) * | 2022-10-08 | 2024-04-11 | Lingyi Biotech Co., Ltd. | Construct for enhancing gene expression |
| CN116555266A (zh) * | 2023-06-09 | 2023-08-08 | 呈诺再生医学科技(北京)有限公司 | 肝脏特异性表达的重组启动子和载体及其在肝脏相关疾病治疗中的应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| ATE78293T1 (de) | 1983-05-27 | 1992-08-15 | Texas A & M Univ Sys | Verfahren zur herstellung eines rekombinanten baculovirus-expressionsvektors. |
| DK518384A (da) | 1984-01-31 | 1985-07-01 | Idaho Res Found | Vektor til fremstilling af et gen-produkt i insektceller, fremgangsmaade til dens fremstilling samt dens anvendelse |
| KR100356615B1 (ko) | 1993-07-13 | 2003-04-03 | 아방티 파르마 소시에테 아노님 | 결함아데노바이러스벡터및유전자치료에서그의사용 |
| US6204059B1 (en) | 1994-06-30 | 2001-03-20 | University Of Pittsburgh | AAV capsid vehicles for molecular transfer |
| JP2001500376A (ja) | 1996-09-06 | 2001-01-16 | カイロン コーポレイション | 組換えａａｖベクターを使用する治療分子の肝臓特異的送達のための方法および組成物 |
| US6383794B1 (en) * | 1998-08-24 | 2002-05-07 | Uab Research Foundation | Methods of producing high titer recombinant adeno-associated virus |
| US6221349B1 (en) | 1998-10-20 | 2001-04-24 | Avigen, Inc. | Adeno-associated vectors for expression of factor VIII by target cells |
| US6200560B1 (en) | 1998-10-20 | 2001-03-13 | Avigen, Inc. | Adeno-associated virus vectors for expression of factor VIII by target cells |
| US6723551B2 (en) | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
| AU2003212708A1 (en) | 2002-03-05 | 2003-09-16 | Stichting Voor De Technische Wetenschappen | Baculovirus expression system |
| ATE549037T1 (de) | 2004-09-22 | 2012-03-15 | St Jude Childrens Res Hospital | Verbesserte expression von faktor-ix in gentherapie-vektoren |
| CN1286981C (zh) * | 2004-11-30 | 2006-11-29 | 华中科技大学同济医学院附属同济医院 | 表达人类cyp2j2反义基因的重组腺相关病毒及其制备方法 |
| EP1739179A1 (en) * | 2005-06-30 | 2007-01-03 | Octapharma AG | Serum-free stable transfection and production of recombinant human proteins in human cell lines |
| US7943374B2 (en) * | 2005-08-21 | 2011-05-17 | Markus Hildinger | Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb |
| US7943379B2 (en) | 2008-04-30 | 2011-05-17 | Nationwide Children's Hospital, Inc. | Production of rAAV in vero cells using particular adenovirus helpers |
| GB0911870D0 (en) | 2009-07-08 | 2009-08-19 | Ucl Business Plc | Optimised coding sequence and promoter |
| CN103215308B (zh) * | 2013-02-01 | 2015-12-23 | 中国科学院苏州生物医学工程技术研究所 | 表达重组人fviii的整合质粒、细胞株及其构建方法和应用 |
| CN112538501A (zh) * | 2013-09-12 | 2021-03-23 | 生物马林药物股份有限公司 | 腺相关病毒因子viii载体 |
-
2014
- 2014-09-10 CN CN202011117582.3A patent/CN112538501A/zh active Pending
- 2014-09-10 SI SI201431647T patent/SI3044231T1/sl unknown
- 2014-09-10 RS RS20201018A patent/RS61039B1/sr unknown
- 2014-09-10 US US14/482,648 patent/US9504762B2/en active Active
- 2014-09-10 PE PE2016000353A patent/PE20160769A1/es unknown
- 2014-09-10 HU HUE14771729A patent/HUE050484T2/hu unknown
- 2014-09-10 LT LTEP14771729.2T patent/LT3044231T/lt unknown
- 2014-09-10 MX MX2016003262A patent/MX2016003262A/es unknown
- 2014-09-10 JP JP2016542067A patent/JP6735672B2/ja active Active
- 2014-09-10 EP EP20182970.2A patent/EP3770169A1/en active Pending
- 2014-09-10 AU AU2014318890A patent/AU2014318890B2/en active Active
- 2014-09-10 EP EP14771729.2A patent/EP3044231B1/en active Active
- 2014-09-10 NZ NZ716549A patent/NZ716549A/en unknown
- 2014-09-10 CA CA3178384A patent/CA3178384A1/en active Pending
- 2014-09-10 KR KR1020167009492A patent/KR102484396B1/ko active IP Right Grant
- 2014-09-10 PL PL14771729T patent/PL3044231T3/pl unknown
- 2014-09-10 KR KR1020227046233A patent/KR20230006058A/ko not_active Application Discontinuation
- 2014-09-10 ES ES14771729T patent/ES2813698T3/es active Active
- 2014-09-10 WO PCT/US2014/054960 patent/WO2015038625A1/en active Application Filing
- 2014-09-10 CN CN201480050615.3A patent/CN105636981B/zh active Active
- 2014-09-10 CA CA3178379A patent/CA3178379A1/en active Pending
- 2014-09-10 SG SG11201601932UA patent/SG11201601932UA/en unknown
- 2014-09-10 DK DK14771729.2T patent/DK3044231T3/da active
- 2014-09-10 CA CA2921232A patent/CA2921232C/en active Active
- 2014-09-10 RU RU2016113702A patent/RU2710307C2/ru active
- 2014-09-10 PT PT147717292T patent/PT3044231T/pt unknown
- 2014-09-12 AR ARP140103423A patent/AR097657A1/es unknown
- 2014-09-12 TW TW103131665A patent/TWI632239B/zh active
-
2016
- 2016-02-18 PH PH12016500328A patent/PH12016500328A1/en unknown
- 2016-03-03 IL IL244404A patent/IL244404B/en unknown
- 2016-03-04 CL CL2016000502A patent/CL2016000502A1/es unknown
- 2016-03-11 MX MX2021012014A patent/MX2021012014A/es unknown
- 2016-10-14 US US15/294,310 patent/US10463718B2/en active Active
- 2016-12-22 HK HK16114574A patent/HK1226416A1/zh unknown
-
2017
- 2017-11-17 US US15/816,596 patent/US20180161403A1/en not_active Abandoned
-
2019
- 2019-08-14 JP JP2019148912A patent/JP2019193675A/ja active Pending
- 2019-09-30 US US16/588,130 patent/US11406690B2/en active Active
-
2020
- 2020-08-25 HR HRP20201324TT patent/HRP20201324T1/hr unknown
- 2020-08-31 CY CY20201100814T patent/CY1124213T1/el unknown
-
2021
- 2021-02-18 JP JP2021024332A patent/JP2021072871A/ja not_active Withdrawn
- 2021-09-30 IL IL286859A patent/IL286859A/en unknown
-
2022
- 2022-06-30 US US17/854,286 patent/US20220339262A1/en active Pending
-
2023
- 2023-01-11 HU HUS2300003C patent/HUS2300003I1/hu unknown
- 2023-01-12 NO NO2023003C patent/NO2023003I1/no unknown
- 2023-02-02 FR FR23C1007C patent/FR23C1007I1/fr active Active
- 2023-02-08 FI FIC20230007C patent/FIC20230007I1/fi unknown
- 2023-02-20 LT LTPA2023508C patent/LTPA2023508I1/lt unknown
- 2023-02-24 NL NL301222C patent/NL301222I2/nl unknown
- 2023-08-04 JP JP2023127698A patent/JP2023133597A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR097657A1 (es) | Vectores de virus adenoasociados de factor viii | |
| Lee et al. | Design strategy for 25% external quantum efficiency in green and blue thermally activated delayed fluorescent devices. | |
| EP3792348A3 (en) | Mutated rep encoding sequences for use in aav production | |
| WO2008153869A3 (en) | Supported iridium catalysts | |
| JP2015514128A5 (es) | ||
| ATE512980T1 (de) | Polypeptide mit beta-glucosidase-aktivität sowie diese codierende polynukleotide | |
| EA201390389A1 (ru) | Полупроводящая полиолефиновая композиция, содержащая эпоксигруппы | |
| BR112014015063A2 (pt) | composição, composição de isolamento de cabo e processo para preparar um cabo isolado | |
| Hinou et al. | H-bonding promotion of peptide solubility and cyclization by fluorinated alcohols | |
| Bartoli et al. | New type of estimate for the smallest size of complete arcs in PG (2, q) | |
| Koli et al. | Matrix converter technology: a review paper | |
| Medana et al. | and Claudio Baiocchi1 | |
| Shin | Novel buffer layers for improving the performance of polymer solar cells | |
| WO2008104575A3 (en) | Immune system mediator | |
| 강태화 et al. | Microsatellite Marker Development and Genetic Structure of Lymantria dispar asiatica Vnukovskij, 1926 (Lepidoptera: Erebidae) using Next Generation Sequencing | |
| Nakamura | Showcasing research from the group of Dr Ryuhei Nakamura at RIKEN Center for Sustainable Resource Science (CSRS), Japan. | |
| Grubbs | Synthesis of polymers with controlled stereochemistry using olefin metathesis catalysts | |
| Zeng | Showcasing research from The Biomass Chemical Conversion Lab (BCCL, Led by Prof. Lu Lin), College of Energy, Xiamen University, Xiamen, China. | |
| Kim et al. | A study on the Economical Installation of Ground Electrodes for Distribution Line | |
| 임경근 et al. | Energy level tailoring for high power conversion efficiency of perovskite solar cells using self-organized polymeric hole extraction layers with high work function | |
| 강태화 et al. | Microsatellite Marker Development of Lymantria dispar asiatica Vnukovskij, 1926 (Lepidoptera: Erebidae) using Next Generation Sequencing | |
| Kang et al. | A new alternative hole-transporting layer to PEDOT: PSS for realizing highly efficient all solution-processable PLEDs | |
| Шеремета et al. | no xåðåìåòà, ê. ò. í.;. P. Âëàñþê, ê. ò. í. qonqPÁ ÂÈÌPpÞÂÍÍ “ZopÌeŠpPÂ) nŠÈpÈonËÞqÍÈÊ | |
| Ko et al. | Solar Module Cleaning System in Desert | |
| 周欣然 et al. | Lowering the Operational Voltage of Single-Layer Polymer Electroluminescent Devices by Using CuO_x Modifying Indium-Tin Oxide Electrode |